Randomized Phase II Trials: Inevitable or Inadvisable?

被引：65

作者：

Gan, Hui K.

Grothey, Axel

Pond, Gregory R.

Moore, Malcolm J.

Siu, Lillian L. ^{[1
]}

Sargent, Daniel

机构：

[1] Princess Margaret Hosp, Div Med Oncol Haematol, Toronto, ON M5G 2M9, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期

关键词：

ADVANCED PANCREATIC-CANCER; DOSE RATE INFUSION; CLINICAL-TRIALS; PLUS GEMCITABINE; 30-MINUTE INFUSION; DESIGN ISSUES; CARCINOMA; FUTURE; MULTICENTER; OXALIPLATIN;

D O I：

10.1200/JCO.2009.26.3343

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：2641 / 2647

页数：7

共 46 条

[11] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[12]

El-Maraghi RH, 2008, J CLIN ONCOL, V26, P1346, DOI 10.1200/JCO.2007.13.5913

[13] Industry, clinical trials, and the cost of cancer drugs: An investor's perspective [J].

Fiorino, Tony .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :E21-E23

[14] Some design issues in trials of microbicides for the prevention of HIV infection [J].

Fleming, TR ;

Richardson, BA .

JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (04) :666-674

[15] Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer [J].

Heinemann, Volker ;

Quietzsch, Detlef ;

Gieseler, Frank ;

Gonnermann, Michael ;

Schoenekaes, Herbert ;

Rost, Andreas ;

Neuhaus, Horst ;

Haag, Caroline ;

Clemens, Michael ;

Heinrich, Bernard ;

Vehling-Kaiser, Ursula ;

Fuchs, Martin ;

Fleckenstein, Doris ;

Gesierich, Wolfgang ;

Uthgenannt, Dirk ;

Einsele, Hermann ;

Holstege, Axel ;

Hinke, Axel ;

Schalhorn, Andreas ;

Wilkowski, Ralf .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (24) :3946-3952

[16] Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer:: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group [J].

Herrmann, Richard ;

Bodoky, Gyoergy ;

Ruhstaller, Thomas ;

Glimelius, Bengt ;

Bajetta, Emilio ;

Schueller, Johannes ;

Saletti, Piercarlo ;

Bauer, Jean ;

Figer, Arie ;

Pestalozzi, Bernhard ;

Koehne, Claus-Henning ;

Mingrone, Walter ;

Stemmer, Salomon M. ;

Tamas, Karin ;

Kornek, Gabriela V. ;

Koeberle, Dieter ;

Cina, Susanne ;

Bernhard, Juerg ;

Dietrich, Daniel ;

Scheithauer, Werner .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) :2212-2217

[17]

Kindler HL, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.12.0949

[18] Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer [J].

Kindler, HL ;

Friberg, G ;

Singh, DA ;

Locker, G ;

Nattam, S ;

Kozloff, M ;

Taber, DA ;

Karrison, T ;

Dachman, A ;

Stadler, WM ;

Vokes, EE .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8033-8040

[19] Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials [J].

Korn, Edward L. ;

Liu, Ping-Yu ;

Lee, Sandra J. ;

Chapman, Judith-Anne W. ;

Niedzwiecki, Donna ;

Suman, Vera J. ;

Moon, James ;

Sondak, Vernon K. ;

Atkins, Michael B. ;

Eisenhauer, Elizabeth A. ;

Parulekar, Wendy ;

Markovic, Svetomir N. ;

Saxman, Scott ;

Kirkwood, John M. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :527-534

[20] Randomized phase II designs in cancer clinical trials: Current status and future directions [J].

Lee, JJ ;

Feng, L .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4450-4457

← 1 2 3 4 5 →